Annexin V analysis of apoptotic responses in 15 AML patients
Patient no. . | Incubation time, h . | AS602868, 10 μM, % . | VP16, 10 μM, % . | AS602868, 10 μM; VP16, 10 μM, % . | IC50, μM; AS602868 . |
---|---|---|---|---|---|
1 | 72 | 87 | 1 | 89 | 4 |
2 | 72 | 73 | 7 | 93 | 1.4 |
3 | 72 | 63 | –16 | 75 | 2.2 |
4 | 72 | 71 | 64 | 78 | 1 |
5 | 48 | 45 | 85 | 94 | 14 |
6 | 72 | 34 | 16 | 59 | 14 |
7 | 72 | 17 | 79 | 86 | > 30 |
8 | 72 | 78 | 28 | 87 | 2.8 |
9 | 72 | 92 | 58 | 97 | 0.6 |
10 | 72 | 92 | ND | ND | 2.8 |
11 | 72 | 39 | 31 | 66 | 5 |
12 | 72 | 36 | 39 | 44 | > 30 |
13 | 72 | 65 | 1 | 79 | 8 |
14 | 72 | 64 | 77 | 87 | 7.1 |
15 | 72 | 23 | 60 | 77 | > 30 |
Patient no. . | Incubation time, h . | AS602868, 10 μM, % . | VP16, 10 μM, % . | AS602868, 10 μM; VP16, 10 μM, % . | IC50, μM; AS602868 . |
---|---|---|---|---|---|
1 | 72 | 87 | 1 | 89 | 4 |
2 | 72 | 73 | 7 | 93 | 1.4 |
3 | 72 | 63 | –16 | 75 | 2.2 |
4 | 72 | 71 | 64 | 78 | 1 |
5 | 48 | 45 | 85 | 94 | 14 |
6 | 72 | 34 | 16 | 59 | 14 |
7 | 72 | 17 | 79 | 86 | > 30 |
8 | 72 | 78 | 28 | 87 | 2.8 |
9 | 72 | 92 | 58 | 97 | 0.6 |
10 | 72 | 92 | ND | ND | 2.8 |
11 | 72 | 39 | 31 | 66 | 5 |
12 | 72 | 36 | 39 | 44 | > 30 |
13 | 72 | 65 | 1 | 79 | 8 |
14 | 72 | 64 | 77 | 87 | 7.1 |
15 | 72 | 23 | 60 | 77 | > 30 |
Statistical analysis by paired ANOVA and PLSD Fisher test (a probability of < .05 is considered significant).
ND indicates not determined.